Naidoo Kirusha, Lessells Richard J, Dorward Jienchi, Moosa Mahomed Y S, Sookrajh Yukteshwar, Moodley Pravi, Drain Paul K, Garrett Nigel
Department of HIV Vaccines and Pathogenesis, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
South Afr J HIV Med. 2025 Apr 23;26(1):1701. doi: 10.4102/sajhivmed.v26i1.1701. eCollection 2025.
The integrase strand transfer inhibitor, dolutegravir (DTG), is widely used in first- and second-line antiretroviral therapy (ART) regimens in South Africa. We describe an adult with virological failure on second-line tenofovir/lamivudine/dolutegravir (TLD2) and rapid emergence of DTG resistance within 3 months, while receiving rifapentine-based tuberculosis preventive therapy.
整合酶链转移抑制剂度鲁特韦（DTG）在南非的一线和二线抗逆转录病毒治疗（ART）方案中被广泛使用。我们描述了一名成年人，其在接受基于利福喷丁的结核病预防性治疗时，二线替诺福韦/拉米夫定/度鲁特韦（TLD2）治疗出现病毒学失败，且在3个月内迅速出现DTG耐药。
